

RECEIVED  
#12

FEB 15 2002

TECH CENTER 1600/2900  
Patent

Attorney's Docket No. 010830-117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Patent Application of )  
Krzysztof MASTERNAK et al. )  
Application No.: 09/840,243 ) Group Art Unit: 1623  
Filing Date: April 24, 2001 ) Examiner: Unassigned  
For: NEW TRANSCRIPTION FACTOR )  
OF MHC CLASS II GENES, SUB- )  
STANCES CAPABLE OF INHIBITING )  
THIS NEW TRANSCRIPTION )  
FACTOR AND MEDICAL USES )  
OF THESE SUBSTANCES )

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING  
REQUIREMENTS AND PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on December 13, 2001 and prior to examination on the merits, please amend the above-identified application as follows:

**IN THE SPECIFICATION:**

Kindly replace the paragraph beginning at page 62, line 31 with the following:

--In vitro transcription-translation reactions and electrophoretic mobility shift assays

(EMSA) using nuclear extracts and in vitro translated proteins were done as described<sup>9,22,50</sup>.

The production of polyclonal rabbit antisera specific for RFX5 and RFXAP and their use in supershift experiments have also been described<sup>10</sup>. The monoclonal anti-FLAG antibody (M2, Kodak) was used in supershift experiments at a final concentration of 20 ng/ml. The RFXANK cDNA tagged with a FLAG epitope at its N terminus was constructed as follows: The entire RFXANK open reading frame was amplified from pEBO-RFXANK plasmid by PCR with primers 3'p33 (described above) and FLAG-5'p33 (5'-CCGTACGCGTCTAGAATGGATTACAAAGACGATGACGATAAGA TGGAGCTTACCCAGCCTGCAGAAGAC -3') (SEQ ID NO: 9). The FLAG epitope (DYKDDDDK) coding sequence (SEQ ID NO: 20) is underlined. The PCR product containing the FLAG sequence fused to the 5' end of RFXANK was cloned in pBluescript KS (Stratagene).--

Kindly replace the paragraph beginning at page 67, line 8 with the following:

--Wild type and mutated DRA promoter fragments were constructed by PCR on a DRsyn template. The W box sequence (SEQ ID NO: 21) GGACCCTTGCAAG was mutated to (SEQ ID NO: 22) TACATAGCGTACGT. The X2 box sequence TGCGTCA was mutated to GACAAGT. The mutated X and Y templates were described previously.

The  $\Delta$  Oct template (-150 to -56) was obtained by digestion of the wild type DRsyn

fragment with BglIII.--

Please substitute the enclosed paper copy of the Sequence Listing for the substitute Sequence Listing filed and requested to be entered into the specification on October 4, 2001. Please renumber the pages of the application accordingly.

**REMARKS**

Entry of the foregoing and favorable consideration of the subject application, in light of the following remarks, are respectfully requested.

By the foregoing amendment, the specification has been amended to insert the second substitute Sequence Listing provided herewith. Additionally, the paragraph bridging pages 62 and 63 as well as the first full paragraph on page 67 of the specification have been amended to insert sequence identifiers at the appropriate locations therein. No new matter has been added.

In the event that there are any questions relating to this submission, or the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

  
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: February 13, 2002

Attachment to Response to Notice to Comply with Sequence Listing Requirements and  
Preliminary Amendment dated February 13, 2002

**Page 62, Paragraph Beginning at Line 31**

In vitro transcription-translation reactions and electrophoretic mobility shift assays (EMSA) using nuclear extracts and in vitro translated proteins were done as described[9,22,50]<sup>22,50</sup>. The production of polyclonal rabbit antisera specific for RFX5 and RFXAP and their use in supershift experiments have also been described[10]<sup>10</sup>. The monoclonal anti-FLAG antibody (M2, Kodak) was used in supershift experiments at a final concentration of 20 ng/ml. The RFXANK cDNA tagged with a FLAG epitope at its N terminus was constructed as follows: The entire RFXANK open reading frame was amplified from pEBO-RFXANK plasmid by PCR with primers 3'p33 (described above) and FLAG-5'p33 (5'-CCGTACGCGTCTAGAATGGATTACAAAGACGATGACGATA AGATGGAGCTTACCCAGCCTGCAGAAGAC -3') (SEQ ID NO: 9). The FLAG epitope (DYKDDDDK) coding sequence (SEQ ID NO: 20) is underlined. The PCR product containing the FLAG sequence fused to the 5' end of RFXANK was cloned in pBluescript KS (Stratagene).

**Page 67, Paragraph Beginning at Line 8**

Wild type and mutated DRA promoter fragments were constructed by PCR on a DRsyn template. The W box sequence (SEQ ID NO: 21) GGACCCTTGCAAG was mutated to (SEQ ID NO: 22) TACATAGCGTACGT. The X2 box sequence TGCGTCA was mutated to GACAAGT. The mutated X and Y templates were described previously.

Application Serial No. 09/840,243  
Attorney's Docket No. 010830-117  
Mark-up of Specification - Page 2 of 2

**Attachment to Response to Notice to Comply with Sequence Listing Requirements and  
Preliminary Amendment dated February 13, 2002**

The [§]  $\Delta$  Oct template (-150 to -56) was obtained by digestion of the wild type DRsyn fragment with BglII.